Scarica l'app Stockscreener
18.60
6.96%
1.21
Dopo l'orario di chiusura:
18.99
0.39
+2.10%
Precedente Chiudi:
$17.39
Aprire:
$17.82
Volume 24 ore:
1.45M
Relative Volume:
1.44
Capitalizzazione di mercato:
$1.14B
Reddito:
$13.73M
Utile/perdita netta:
$-114.48M
Rapporto P/E:
-10.10
EPS:
-1.8418
Flusso di cassa netto:
$-78.49M
1 W Prestazione:
+14.39%
1M Prestazione:
+21.33%
6M Prestazione:
+36.26%
1 anno Prestazione:
-23.46%
Intervallo 1D:
$17.50
$19.02
Intervallo di 1 settimana:
$16.10
$19.02
Portata 52W:
$12.12
$35.34
Janux Therapeutics Inc Stock (JANX) Company Profile
Nome
Janux Therapeutics Inc
Settore
Industria
Telefono
(858) 751-4493
Indirizzo
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
18.60 | 1.06B | 13.73M | -114.48M | -78.49M | -1.8418 |
VRTX
Vertex Pharmaceuticals Inc
|
547.59 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
828.50 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,011.11 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
138.89 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.58 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Downgrade | Barclays | Overweight → Underweight |
| 2026-04-15 | Downgrade | UBS | Buy → Neutral |
| 2025-11-18 | Iniziato | Wolfe Research | Peer Perform |
| 2025-09-17 | Iniziato | Barclays | Overweight |
| 2025-09-10 | Iniziato | Stifel | Buy |
| 2025-09-10 | Iniziato | Truist | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-08-19 | Iniziato | Piper Sandler | Overweight |
| 2025-07-11 | Iniziato | Raymond James | Outperform |
| 2024-12-03 | Reiterato | BTIG Research | Buy |
| 2024-12-03 | Reiterato | H.C. Wainwright | Buy |
| 2024-11-22 | Iniziato | Leerink Partners | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-09-06 | Iniziato | Stifel | Buy |
| 2024-05-30 | Iniziato | Scotiabank | Sector Perform |
| 2024-03-21 | Iniziato | BTIG Research | Buy |
| 2024-03-20 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-04-06 | Iniziato | Wedbush | Outperform |
| 2022-11-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Janux Therapeutics Inc Borsa (JANX) Ultime notizie
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know - TradingView
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile? - Sahm
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $14 to $60 - Moomoo
Janux (JANX) Latest Quarter: EPS Lands Above Forecast; Market Reaction: Shares Finish 3.30% Higher on the DayEstimate Revision Count - vinanet.vn
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Dimensional Fund Advisors LP Has $1.34 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX) and Ginkgo Bioworks Holdings (DNA) - The Globe and Mail
Point72 reports 3.3% beneficial stake in Janux Therapeutics (JANX) via managed fund - Stock Titan
Janus Henderson Group (JANX) reports 172,229 Janux Therapeutics shares under management - Stock Titan
JANX Stock Edges Up After Hours After Discontinuing Cancer Program In Favor Of Remaining Pipeline - Stocktwits
Stifel Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Janux Therapeutics (JANX) Gains 0.91% as Shares Firmly Hold Above $15.84 SupportHigh Conviction Picks - Vinanet
Equities Analysts Set Expectations for JANX Q3 Earnings - MarketBeat
HC Wainwright Has Negative Outlook of JANX FY2030 Earnings - MarketBeat
Why (JANX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Janux Therapeutics (JANX) Is Up 7.1% After Reporting Narrower Net Losses And Improved Earnings Profile - Yahoo Finance
Janus Living Prices Share Offering - marketscreener.com
Janux Therapeutics Inc (JANX) Stock News Today - TradingKey
RBC Adjusts Price Target on Janux Therapeutics to $34 From $30, Maintains Outperform Rating - Moomoo
Analysts Have Lowered Expectations For Janux Therapeutics, Inc. (NASDAQ:JANX) After Its Latest Results - simplywall.st
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $45 - Moomoo
Janux Therapeutics (NASDAQ:JANX) Announces Earnings Results - MarketBeat
Bank of America Securities Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Janux Therapeutics Inc (JANX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Janux Therapeutics, Inc. Stock 12‑Month Price Target Cut to $33.25, Implies 107% Upside - TradingView
Janux Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights - BioSpace
JANX Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Drives FocusRevenue Guidance Update - vinanet.vn
Janux Therapeutics earnings missed by $0.08, revenue fell short of estimates - Investing.com Canada
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
Janux Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Janux Therapeutics 2Q 2026: Revenue $10.3M, EPS $(0.35) — 10-Q Summary - TradingView
JANX: Clinical pipeline advanced and net loss narrowed, supported by nearly $1B in liquidity - TradingView
Earnings Flash (JANX) Janux Therapeutics, Inc. Reports Q2 Revenue $10.3M, vs. FactSet Est of $19.1M - marketscreener.com
JANX: Revenue from BMS collaboration boosted H1 2026 results; net loss narrowed, cash remains strong - TradingView
Janux Therapeutics (NASDAQ: JANX) posts Q2 loss on collaboration revenue - Stock Titan
Janux Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Janux Therapeutics posts $970.9M cash; Q2 net loss $22.0M and revenue $10.3M - TradingView
BRIEF-Janux Therapeutics Q2 Basic EPS USD -0.35 - TradingView
JANX Q2'26 Earnings: revenue estimate is 19.07M USD - TradingView
Janux Therapeutics, Inc. (JANX) Stock Analysis: A Biotech Gamble with 142% Potential Upside - DirectorsTalk Interviews
Janux Therapeutics (JANX) Holds at $15.32 as Biotech Names Find FootingKAMA Signal - vinanet.vn
Janux Therapeutics (JANX) Pulls Back to $15.17 as Biotech Volatility PersistsLast Point Resistance - vinanet.vn
Form 4 Janux Therapeutics Inc For: 31 July By Investing.com - Investing.com Canada
Understanding Momentum Shifts in (JANX) - Stock Traders Daily
Janux Therapeutics, Inc. Revenue Breakdown – NASDAQ:JANX - TradingView
Janux Therapeutics (JANX) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Readystate Asset Management LP Has $1.52 Million Stake in Janux Therapeutics, Inc. $JANX - MarketBeat
Weiss Asset Management LP Takes Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics Inc (JANX) Balance Sheet - TradingKey
JANX|Janux Therapeutics Inc|Price:15.680|Chg%:+0.350 - TradingKey
Janux Therapeutics Inc (JANX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Janux Therapeutics Inc Azioni (JANX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.00%
3.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):